Comparison of terbinafine and clotrimazole in treating tinea pedis.

OBJECTIVE--To compare the efficacy and safety of terbinafine 1% cream and clotrimazole 1% cream in the treatment of tinea pedis. DESIGN--Multicentre, double blind parallel group study. SETTING--32 general practices and one hospital. PATIENTS--256 patients with mycologically confirmed tinea pedis. Of the 211 patients evaluable, 107 were randomised to terbinafine (75 male, 32 female; mean (range) age 40 (12-81) years) and 104 to clotrimazole (79 male, 25 female; mean (range) age 36 (12-71) years). INTERVENTIONS--Terbinafine 1% cream applied twice daily for one week and inert cream applied twice daily for the next three weeks. Clotrimazole 1% cream applied twice daily for four weeks. MAIN OUTCOME MEASURES--Mycological cure (negative results on microscopy and culture) and effective treatment (mycological cure plus no or minimal signs and symptoms) measured at weeks 1, 2, 3, 4, and 6. RESULTS--At week four rates of mycological cure were 93.5% for terbinafine and 73.1% for clotrimazole (p = 0.0001); and at week six 97.2% for terbinafine and 83.7% for clotrimazole (p = 0.001). Rates of effective treatment at week 4 were 89.7% for terbinafine and 58.7% for clotrimazole (p = 0.0001); and 89.7% for terbinafine and 73.1% for clotrimazole (p = 0.002) at week 6. CONCLUSION--These results indicate that a one week course of terbinafine 1% cream is more effective in the treatment of tinea pedis than a four week course of clotrimazole 1% cream, both in terms of mycological cure and effective treatment.     

口服特比萘芬联合外用联苯苄唑乳膏治疗足癣长期临床研究

目的 为足癣治疗提供较理想的方案.方法 盐酸特比萘芬250 mg,口服1次/d;1%联苯苄唑乳膏,外用1次/d.250例足癣患者随机入组.A组口服1周加外用1周,B组口服1周加外用2周,C组口服2周加外用1周,D组口服2周加外用2周,E组单独外用4周.在治疗结束时、治疗结束后4周、24周、40周、56周、72周时对各组的疗效、复发率进行评价.结果 在停药后第24周时,A、B、C、D组与E组疗效比较差异有统计学意义.在停药后第40周、56周、72周时,D组与A、B组疗效比较差异也出现统计学意义.在停药后24周、40周时,A、B、C、D组真菌学疗效与E组比较差异有统计学意义.在停药56周、72周时,D组与A、B组真菌学疗效比较差异也出现统计学意义.在停药40周时,A、B、C、D组与E组复发率比较差异有统计学意义.在停药56周、72周时,D组与A、B组复发率比较差异也出现统计学意义.结论 口服特比萘芬2周联合外用1%联苯苄唑乳膏2周治疗足癣的有效率和真菌学疗效最高,复发率最低.     

趾间型足癣患者细菌菌种分布特征

目的了解趾间型足癣患者趾间和健康志愿者趾间细菌菌种分布特征。方法对37例经临床和真菌镜检确诊的趾间型足癣患者的趾间进行细菌培养,然后给予1%联苯苄唑霜1次/d外用治疗4周,在治疗后的第1、2、4周分别对趾间再进行细菌培养。33例健康志愿者作为对照。结果健康志愿者趾间细菌培养葡萄球菌属占92.5%,其中表皮葡萄球菌占32.5%,未分离到金黄色葡萄球菌。趾间型足癣患者细菌培养葡萄球菌属占74.4%,其中金黄色葡萄球菌占27.9%,表皮葡萄球菌仅占2.3%,还分离到化脓性链球菌、粪肠球菌、屎肠球菌、奇异变形杆菌、铜绿假单胞菌等。经过4周的外用联苯苄唑霜治疗,金黄色葡萄球菌消失,表皮葡萄球菌又成为优势菌（37.5%）。结论趾间型足癣患者趾间金黄色葡萄球菌的分离率明显高,此乃足癣继发细菌感染的主要致病菌,因此积极治疗足癣对预防足癣合并症有非常重要的意义。     

特比萘芬短程口服加外用特比萘芬治疗中重度皮肤癣菌病的临床对照研究

目的为治疗中、重度皮肤癣菌病选择合适的方法。方法采用开放、随机对照的平行研究。将临床和真菌镜检确诊的中重度体、股癣和手、足癣患者随机分入A、B、C、D四组,A组口服特比萘芬片联合外用特比萘芬乳膏,疗程7d;B组常规口服特比萘芬片,疗程14d;C组常规外用特比萘芬乳膏,疗程14d;D组外用联苯苄唑乳膏,疗程4周。对各组的临床疗效、安全性、患者对治疗的满意度等进行分析。结果①真菌学疗效:停药后4周时A组手、足癣患者的真菌清除率最高为96.65%,与D组比较(65.00%)差异有显著性。②临床疗效:停药后2周和4周时A组手足癣患者的治愈率分别为93.33%和90.00%,与D组(68%、64%)比较差异有显著性。③患者满意度:在本研究的四组中,A组患者对疗效的满意度最高,与C组、D组比较差异有显著性;患者的综合满意度(包括对治疗费用、安全性等方面)A组最高,与C组、D组比较差异有显著性。D组患者对费用的接受程度最高,A组优于B组,有极显著的统计学差异。治疗结束后患者对安全性的接受程度四组间没有显著差异。结论特比萘芬口服加外用1周的“1 1”短程联合疗法治疗中、重度皮肤癣菌病的疗效高、疗程短、依从性好,患者满意度高。     

30例犬小孢子菌致体癣病例的临床分析

目的 通过对30例犬小孢子菌致体癣病例的临床分析,探讨城市犬小孢子菌病的常见感染来源及防治方案.方法 收集2012年6～7月就诊于我院有宠物接触史(猫、狗)的体癣患者30例,对其致病菌种做真菌培养鉴定,对结果进行临床分析.给予患者外用联苯苄唑软膏或特比萘芬软膏治疗.结果 30例患者均在发病前接触过猫或狗,病程不长,真菌培养结果显示均为犬小孢子菌,经治疗后均痊愈.结论 30例犬小孢子菌致体癣患者皮损特征相似,外用抗真菌软膏可得到有效治疗.     

足癣义诊患者临床分析及特比萘芬联合疗法疗效观察

目的分析西京医院皮肤科近3a来每年足癣义诊患者基本情况,并对口服特比萘芬片结合外用特比萘芬乳膏治疗足癣进行疗效分析。方法回顾性分析3a来每年夏天足癣义诊活动中就诊于西京医院皮肤科足癣患者情况。其中2007年义诊患者随机分为3组。I为单纯特比萘芬乳膏治疗组,外用特比萘芬乳膏2次/d×2周;Ⅱ为单纯口服特比萘芬片组,给予口服特比萘芬片（兰美抒片）250mg/d×1周;Ⅲ组给予口服特比萘芬,250mg/d×1周,联合外用特比萘芬乳膏,2次/d×2周。3组分别在患者治疗1个月后电话随访。结果3a足癣义诊周患者平均真菌阳性率为75.76%;采用特比萘芬联合疗法治疗的患者,有效率高达85.26%,复发率不足6%。结论特比萘芬联合疗法治疗足癣疗效肯定。     

2%硝酸舍他康唑乳膏治疗体股癣和足癣疗效和安全性评价

目的 评价2％硝酸舍他康唑乳膏治疗足癣和体、股癣的疗效及安全性,并与2％硝酸咪康唑乳膏对照。方法 采用多中心随机双盲对照试验。试验组及对照组分别外用2％硝酸舍他康唑乳膏和2％硝酸咪康唑乳膏,每天2次,疗程4周。在治疗开始及治疗2周、4周、6周时进行观察。结果 足癣试验组61例,对照组58例;体、股癣试验组56例,对照组55例完成了观察。足癣在4周时,临床有效率试验组98．36％,对照组93．10％,在6周时分别为100％和98．28％;在4周和6周时真菌学清除率试验组均为95．1％,对照组均为100％;在4周时总有效率试验组98．36％,对照组93．10％,在6周时分别为100％和98．28％。体、股癣在4周时,临床有效率试验组98．21％,对照组92．73％,在6周时分别为100％和98．18％;在4周和6周时真菌学清除率试验组和对照组均为100％;在4周时总有效率试验组98．21％,对照组92．73％,在6周时分别为100％和98．18％。药物不良反应发生率试验组1．7％,对照组0．9％,表现为局部刺激。结果 显示2％硝酸舍他康唑乳膏治疗足癣和体、股癣的疗效及安全性与2％硝酸咪康唑乳膏相似（P〉0．05）。结论 2％硝酸舍他康唑乳膏治疗足癣和体、股癣有效、安全。     

萘替芬酮康唑乳膏每日1次治疗足癣疗效观察

目的观察萘替芬酮康唑乳膏1次/d治疗足癣的效果与安全性。方法将参与试验的足癣患者随机分组,试验组每晚1次外用萘替芬酮康唑乳膏,对照组早晚各1次外用萘替芬酮康唑乳膏。连续用药4周,于治疗前,用药2周、4周及停药2周后分别进行症状和体征评分。结果治疗结束和停药2周时,两组的临床疗效无显著差异(P>0.05)。治疗2周时试验组和对照组的真菌清除率分别为78.6%和90.3%,有显著差异(P<0.05);治疗结束和停药2周时试验组的真菌清除率分别为92.9%和97.6%,对照组分别为94.4%和98.6%,均无显著差异(P>0.05)。结论萘替芬酮康唑乳膏1次/d治疗足癣疗效好,简便易行,安全性高。     

萘替芬酮康唑乳膏治疗股癣疗效观察

目的观察萘替芬酮康唑乳膏治疗股癣疗效和安全性。方法将160例患者随机分为治疗组和对照组,治疗组外用萘替芬酮康唑乳膏;对照组外用硝酸咪康唑乳膏,均早晚各涂一次。用药2周及停药3周后分别进行临床疗效和真菌学疗效评价。结果治疗2周时治疗组有效率为92.50%,而对照组有效率为76.25%,两组间差异有统计学意义(P<0.05)。治疗2周时真菌清除率治疗组97.50%,对照组87.50%,两组间差异有统计学意义(P<0.05)。停药3周时治疗组有效率为96.25%,对照组有效率为75.00%,两组间差异有统计学意义(P<0.05)。停药3周时真菌学清除率治疗组97.50%,对照组85.00%,两组间差异有统计学意义(P<0.05)。无明显不良反应发生。结论萘替芬酮康唑乳膏治疗股癣安全有效。     

面癣118例的真菌学和临床因素分析

目的探讨面癣的致病菌、临床特点、易感年龄等相关因素。方法分析本院门诊2012年1～6月的真菌直接涂片镜检发现菌丝或孢子的面癣患者。记录患者的一般资料、有无动物接触史、有无并发其他部位浅部真菌病、用药史。取皮屑直接镜检的同时进行真菌培养鉴定。结果面癣见于各年龄段,在51～70岁之间有一个年龄高峰。分离皮肤癣菌103株,包括红色毛癣菌70株(68.0%)、犬小孢子菌21株(20.4%)、须癣毛癣菌10株(9.7%)、石膏样小孢子菌2株(1.9%)。合并其他浅部真菌病、使用激素类药物、动物接触史是面癣发病的重要因素。部分炎症明显的面癣使用医用拭子取材,可以提高真菌涂片和培养的质量。结论不典型的面癣容易误诊,需要高质量的真菌镜检和培养,降低面癣误诊率。     

Achievement of complete mycological cure by topical antifungal agent NND-502 in guinea pig model of tinea pedis

We examined the therapeutic effect of a 1% cream preparation of NND-502, a novel topical antifungal agent, in a guinea pig tinea pedis model produced by infecting the plantar skin of guinea pigs with Trichophyton mentagrophytes. Animals developing tinea pedis were divided into two groups: an untreated control group and a treated group. In the latter group, after confirming infection had been established, the infected animals were topically treated with the NND-502 cream once daily for one week. The animals were reared in a clean environment free from exposure to exogenous dermatophytes. At one week (5 weeks post-infection), 6 weeks (10 weeks post-infection) and 16 weeks (20 weeks post-infection) after completion of the treatment, plantar skin samples were taken from a certain number of both groups of animals. The results demonstrated that all of the animals in the untreated control group and none of those in the treated group were culture-positive in this animal model of tinea pedis. The topical treatment with NND-502 achieved a mycological cure. Thus NND-502 can be considered a promising candidate as a new anti-dermatophytic agent for topical use.     

儿童头癣33例临床分析

目的 观察姜堰地区儿童头癣流行病学、传播方式、病原菌及治疗结果.方法 对我科2006年8月～ 2013年5月诊治的33例儿童头癣病例进行总结分析.结果 33例儿童头癣中白癣24例、黑癣5例、脓癣4例;男19例、女14例;犬小孢子菌22例、紫色毛癣菌2例、须癣毛癣菌3例、断发毛癣菌3例、红色毛癣菌1例、石膏样小孢子菌2例.患者中有动物接触史的占42.42％ （14/33）.经口服特比萘芬或伊曲康唑6～8周,每日用硫磺皂洗头,局部外用萘替芬酮康唑乳膏均取得满意疗效.8周时治愈率分别为87.50％和88.24％,真菌清除率分别为100％和94.12％.结论 近年来本病增多的原因与喂养猫、犬等宠物有关,主要病原菌是亲动物的犬小孢子菌,经综合治疗,疗效满意.     

硝酸舍他康唑乳膏每日1次疗法治疗股癣疗效观察

目的 观察舍他康唑乳膏1次/d疗法治疗股癣的效果与安全性.方法 将参与试验的股癣患者随机分组,试验组每晚1次外用舍他康唑乳膏,对照组早晚各1次外用舍他康唑乳膏,连续用药4周,于治疗前、用药2周、4周及停药后2周分别进行症状和体征评分.结果 治疗结束和停药2周时,两组的临床疗效无显著差异(P＞0.05).治疗2周时试验组和对照组的真菌清除率分别为82.6％和92.5％,有显著差异(P＜0.05);治疗结束和停药2周时试验组的真菌清除率分别为95.9％和97.3％,对照组分别为96.4％和98.6％,均无显著差异(P＞0.05).结论 舍他康唑乳膏1次/d疗法治疗股癣疗效好,简便易行,安全性高.     

Tinea unguium in the north-west of Iran (1996-2004)

Tinea unguium is a common mycosis in many part of the world including Iran. The prevalence of this mycosis varied depending on time, health level and geographical location. To stabilise the etiological, epidemiological and risk factors of tinea unguium in North-west Iran, a study of patients with suspected dermatophyte infections of their nails was carried out between 1996 and 2004. During this study 590 (354 females and 236 males) patients with clinical presentation of fungal infection in fingernails, toenails or in the both sites, were investigated using direct microscopy and culture of clinical samples. Tinea unguium was documented in 41 cases (7%) and among positive cases, 16 cases (39% total positive cases) were female and 25 cases (61% total positive cases) were male. Seventeen patients (41% total positive cases) had tinea unguium in their finger nails and 24 patients (59% total positive cases) had infection in their toe nails. According to the isolated etiologic agent, 66% (19 cases) of tinea unguium infections were caused by zoophilic drematophytes, 31% (9 cases) were caused by anthropophilic drematophytes and 3% (1 case) were caused by geophilic dermatophytes. With regard of sex, tinea unguium did not show a significant difference. The highest prevalence of tinea unguium was found in patients between 11 and 40 years of age. In conclusion the current results identified the etiological agents and epidemiological aspects of tinea unguium in North-west Iran. Tinea unguium in this region is associated with animal husbandry and direct or indirect contact with their products (wool, leather).     

转化医学真菌学实例——直接提取DNA鉴定菌种及体外药敏试验指导诊治面部难辨认癣

目的报道1例由万博节皮菌(趾间毛癣菌有性期)所致面部难辨认癣,取皮损鳞屑直接提取真菌DNA做菌种鉴定,并与真菌培养鉴定结果比较,对培养的菌落直接用抗真菌乳膏做药敏实验指导治疗。方法病变部鳞屑经KOH涂片真菌镜检阳性后,取鳞屑直接提取DNA,以真菌通用引物ITS1/4做PCR扩增后测序;同时从培养生长的菌提取DNA做分子生物学鉴定;并将抗真菌乳膏加入含菌平板孔中观察抑菌圈大小。结果鳞屑直接提取的DNA与培养获得菌落提取的DNA经PCR-测序均鉴定为万博节皮菌,诊断万博节皮菌感染所致面部难辨认癣。镜检阳性后即给予特比萘芬口服(250mg/d)及1%萘替芬-0.25%酮康唑乳膏外用,每周复诊并取鳞屑镜检和培养,基于药物抑菌实验结果指导治疗5周,至临床治愈和真菌培养转阴。结论鳞屑直接提取DNA做PCR-测序能及早明确菌种,待培养菌落长出后做PCR-测序验证,直接用成品抗真菌乳膏做体外药敏实验指导临床选药,动态培养鳞屑以确定疗程。此个体化诊治方案为从临床到实验室、从实验室到临床转化医学真菌学的成功实例。     

Topical Application of Flurandrenolone in the Treatment of Atopic Dermatitis

The effect of flurandrenolone, 0.05%, in a cream base was compared with that of hydrocortisone, 1%, in the same base in 35 cases of atopic dermatitis, using contralateral application technique. The efficacy of flurandrenolone was found to be superior to that of hydrocortisone in 23 instances and equal in 12 cases. A fourfold dilution of this cream, flurandrenolone 0.0125%, was compared with 1% hydrocortisone cream in 18 patients and similar results were obtained. The superiority of flurandrenolone was particularly evident during the first week of application. The therapeutic efficacy of small amounts of flurandrenolone results in economic advantage to the patient and enables him to use applications of this preparation more freely.     

Microsporum canis Infection in Three Familial Cases with Tinea Capitis and Tinea Corporis

We report a familial infection caused by Microsporum canis. The first two patients were a 30-year-old female and her son, a 5-year-old boy, who came in contact with a pet dog at a farm house. The boy then suffered from hair loss for 3 months. There were circular and patchy alopecia with diffuse scaling on his scalp. Meanwhile, his mother also developed patchy erythema and scaling on her face. Several weeks later, the boy’s sister, a 4-year-old girl, was noted to have inconspicuous scaly plaques in the center of her scalp. The development of tinea capitis in the two children and tinea corporis in their mother were diagnosed based on the positive KOH examination. Morphologic characteristics and sequencing of the internal transcribed spacers 1 and 2, amplified from primary culture isolates, confirmed that their infections were caused by the zoophilic M. canis. Repetitive sequence-based molecular typing using the DiversiLab system secreted enzymatic activity analysis, and antifungal susceptibility indicated that these isolates might share the same source. The boy and girl were cured by the treatment with oral itraconazole and topical naftifine–ketoconazole cream after washing the hair with 2 % ketoconazole shampoo, and their mother was successfully treated by terbinafine orally in combination with topical application of naftifine–ketoconazole cream.     

新型酮康唑喷膜对豚鼠体癣模型疗效的观察

目的 观察新型酮康唑喷膜对豚鼠体癣模型的疗效。方法 选择健康豚鼠20只,用穿刺法制备豚鼠体癣模型。将体癣模型随机分A组（新型酮康唑喷膜治疗组）,B组（喷膜基质治疗组）,C组（复方酮康唑霜治疗组）和D组（对照组）。根据豚鼠皮疹和真菌学检查进行疗效评估。结果 A组和C组的豚鼠治疗后局部红斑和水肿明显减轻,与治疗前比较有显著意义（P〈0．05）;停药2周时,A组和C组真菌镜检、培养阴性率均为100％,明显高于B和D组（P〈0．05）。结论 新型酮康唑喷膜对豚鼠体癣模型有良好的抗真菌活性。     

Prevalence of Dermatophytoses in the Zarqa District of Jordan

A total of 350 clinically suspected cases of dermatomycoses were examined for causative fungi during July 1997 to September 1998. Mycotic infection was demonstrable by microscopy and culture in 199 (56.8%) cases. The most common superficial mycotic infections were tinea pedis (35.2%) followed by tinea capitis (23.1%), tinea unguium (21.6%) and tinea corporis (10.6%). Most of the infected patients were 1–9, 20–29 and 30–39 years old. Men were mainly infected with tinea cruris and tinea pedis, while women were infected with tinea pedis, tinea unguium and tinea capitis. The frequencies of etiological agents isolated from patients were as follows: Trichophyton mentagrophytes var. interdigitale (32.7%), T. rubrum (28.6%), Epidermophyton floccosum (20.1%), Microsporum canis (11.1%), T.schoenleinii (4%), T.verrucosum (2%), T.violaceum (1%), and M. gypseum (0.5%). The number of infections varied with the seasons. The highest number of cases of tinea pedis and tinea cruris occurred in the summer months, while tinea capitis, tinea corporis and tinea unguium occurred in the spring and winter months. This revised version was published online in June 2006 with corrections to the Cover Date.     

Enhancement of the topical tolnaftate delivery for the treatment of tinea pedis via provesicular gel systems

Tolnaftate is a thiocarbamate antifungal drug which is therapeutically active against dermatophytes that cause various forms of tinea. Due to the small amount of tolnaftate released from ordinary ointment bases and insufficient penetration through the infected skin layers the need to incorporate the drug in a more suitable pharmaceutical form has evolved. A provesicular system is one such form that can solve these problems. Once in contact with the skin, dilution with moisture occurs and the provesicular system rapidly transforms into a vesicular one. Provesicular systems were prepared according to full-factorial experimental design. Plain provesicular systems were compared with systems containing Phospholipon 80?H and Lipoid S45 as penetration enhancers. Design expert software was used to analyze the effect of formulation variables (type of Span used as well as the presence or the absence of the penetration enhancer and its type) on the dependent variables: percent encapsulation efficiency (EE%), vesicle size and percent in vitro drug released). Three formulations were chosen; a plain provesicular system (PV-2), one containing Phospholipon 80H (PV-6) and another containing Lipoid S45 (PV-10) with the goal to reveal the effect of penetration enhancer on morphology, rheological properties and ex vivo permeation using confocal laser scanning microscopy (CLSM). Analysis of CLSM results showed that the penetration enhancing effect for the tested formulations followed the order PV-10?>?PV-6?>?PV-2. Promising clinically active treatment for tinea patients could be expected as shown by the in vivo permeation results for the provesicular systems as suggested by the CLSM results.